Primer: Beijing Mabworks Biotech (MWB HK) - Aug 2026
Beijing Mabworks Biotech is a clinical-stage biopharmaceutical company with a strategic focus on developing innovative antibody-based therapies...
97 Views
Pre-IPO Biocytogen Pharmaceuticals - The Novel Development Model Offset the Pipeline's Shortcomings
We analyzed the unique development strategy of Biocytogen, and also pointed out the concerns on its pipeline. However, its business model is hard...
474 Views
Keymed Biosciences (2162.HK) - The Pipeline, the Concerns on Valuation Growth & The Trading Strategy
This article mainly analyzed Keymed in terms of the business, the core and key candidates in the pipeline, the concerns about valuation growth...
479 Views
Pre-IPO Beijing Mabworks Biotech - MIL62 Alone Cannot Save the Situation
This article mainly analyzed Mabworks Biotech in terms of the important clinical-stage drug candidates (MIL62, MIL93, MBS301, MIL97, MIL95, MIL86,...
492 Views
No more insights